Cancer Therapy News and Research

RSS

CCM and MD Anderson partner to improve cancer care in China, Singapore

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has signed a multi-year strategic development agreement with The University of Texas MD Anderson Cancer Center, an internationally renowned cancer research, treatment and education center.

6 May 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.

6 May 2015

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

6 May 2015

Researchers study early response of cells to ischemia

A group of researchers from the Lomonosov Moscow State University in collaboration with their Irish colleagues from the University College Cork has studied the early response of cells to ischemia, which is a restriction in blood supply to tissues causing the death of the cell.

6 May 2015

Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).

6 May 2015

St. Jude scientists develop new computer tool to find DNA duplications and deletions in tumors

St. Jude Children's Research Hospital scientists have developed a significantly better computer tool for finding genetic alterations that play an important role in many cancers but were difficult to identify with whole-genome sequencing.

5 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

Frederick Alt honored with 2015 Szent-Györgyi Prize for Progress in Cancer Research

Frederick Alt, PhD, director of the Program in Cellular and Molecular Medicine at Boston Children's Hospital, has been honored with the 2015 Szent-Györgyi Prize for Progress in Cancer Research.

4 May 2015

New discovery may change the principles for treating cancer

Danish researchers from the University of Copenhagen and Herlev Hospital have made a discovery that may change the principles for treating certain types of cancer.

30 Apr 2015

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free DNA (cfDNA), circulating tumor DNA (ctDNA) and microRNAs (miRNAs) are potential indicators for the tumor burden of patients living with cancer.

30 Apr 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer.

29 Apr 2015

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.

28 Apr 2015

Research findings could offer new way to test for chemo brain in patients

UBC research shows that chemotherapy can lead to excessive mind wandering and an inability to concentrate. Dubbed 'chemo-brain,' the negative cognitive effects of the cancer treatment have long been suspected, but the UBC study is the first to explain why patients have difficulty paying attention.

28 Apr 2015

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

27 Apr 2015

Researchers move one step closer to developing effective radiotherapy for lung cancer

Radiotherapy using protons can deliver more accurate treatment to a tumour while reducing the dose to surrounding tissue. However, in mobile organs such as the lung, precise targeting of the dose is difficult. Now researchers have succeeded in making a model of breathing movement that allows for the precise measurement of narrow beams to a dummy tumour by simulating the motion and physical properties of the chest anatomy in a model, the 3rd ESTRO Forum in Barcelona, Spain, will hear today (Monday).

27 Apr 2015

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

Utilising trusted and clinically proven low energy photons, in a dedicated treatment system. Photoelectric Therapy provides a pain free, non-surgical alternative for the treatment of non-melanoma skin cancer, especially those found in sensitive areas of the head and neck...

24 Apr 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

For some time, cancer scientists have considered the toxin, alpha-amanatin derived from "death cap" mushrooms, as a possible cancer treatment. However, due to its penchant for causing liver toxicity, its potential as an effective therapy has been limited.

23 Apr 2015

Purdue University study sheds light on how decitabine drug reverses cell damage

A Purdue University study sheds light on how cell damage is reversed by the cancer drug decitabine and identifies a potential biomarker that could indicate a patient's stage of cancer and response to treatment.

23 Apr 2015

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Without a doubt, one of the most significant developments in thoracic surgery was the advent of video-assisted thoracoscopic surgery or VATS in the 1990s...

22 Apr 2015

Study: Childhood cancer survivors need better care throughout their lives

Children with cancer have a good chance of surviving the disease--today more than 80 percent survive because of advances in treatment and care. However, recent studies have shown that some of these more than 420,000 U.S. childhood cancer survivors face future health-related challenges as they become adults such as a second cancer diagnosis, cardiac failure, or other severe medical complications.

22 Apr 2015

Cancer Therapy News and Research

CCM and MD Anderson partner to improve cancer care in China, Singapore

First patient receives new 'resistance-busting' experimental skin cancer drug

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Researchers study early response of cells to ischemia

Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

St. Jude scientists develop new computer tool to find DNA duplications and deletions in tumors

Researchers identify multiple types of resistance to new targeted lung cancer drug

Frederick Alt honored with 2015 Szent-Györgyi Prize for Progress in Cancer Research

New discovery may change the principles for treating cancer

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

PCDx test performs better than FoundationOne test in clinical study

Research findings could offer new way to test for chemo brain in patients

Molecular Health granted European patent for novel Erythropoietin receptor

Researchers move one step closer to developing effective radiotherapy for lung cancer

Xstrahl introduces Phtotoelectric therapy to the European market at ESTRO 2015

ADCs based on alpha-amanatin may help treat colorectal cancer

Purdue University study sheds light on how decitabine drug reverses cell damage

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Study: Childhood cancer survivors need better care throughout their lives

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News